S. aureus | Laos89 | Vietnam*83 | Cambodia85 | Thailand84 | |
Blood; n=200 (2000–2011) | All specimens; n=4,833 (2016–2017) | Blood and CSF; n=715 (2016–2017) | Blood; n=46 (2007–2010) | Blood; n=1,881 (2004–2010) | |
MRSA | † | 3,302/4,515 (73%) | 476/674 (71%) | 10/46 (22%) | 357/389 (92%) |
Ciprofloxacin | – | 1,720/4,619 (37%) | 297/689 (43%) | – | 7/63 (11%) |
Erythromycin | 70/180 (39%) | 3,861/4,661 (83%) | 545/639 (79%) | 24/46 (52%) | 436/1,785 (24%) |
Gentamicin | 2/166 (1%) | 1,674/4,090 (41%) | 294/637 (46%) | – | 106/719 (15%) |
Penicillin | 158/170 (93%) | 2,347/2,400 (98%) | 490/504 (97%) | 45/46 (98%) | – |
Tetracycline | 39/81 (48%) | – | 24/46 (52%) | – | |
Trimethoprim–sulfamethoxazole | 16/151 (11%) | 1021/4158 (25%) | 233/661 (35%) | 11/46 (24%) | 341/1,828 (19%) |
Vancomycin | 0/52 (0) | 45/2,680 (2%)‡ | 7/565 (1%) | – | 6/1,380 (<1%) |
Note that there are a paucity of published data and the year ranges differ between countries.
*Antimicrobial testing data from Vu et al83 showed as a class of antibiotic rather than antibiotic agent.
†The first MRSA bacteraemia in Laos was identified in 2017.
‡Resistant and intermediate.
CSF, cerebrospinal fluid; MRSA, methicillin-resistant Staphylococcus aureus.